CHICAGO - October 16, 2008 - GE Healthcare Financial Services has agented a $15 million senior secured credit facility for Cytori Therapeutics (NASDAQ: CYTX), a global biotechnology company innovating regenerative medicine through the development of proprietary treatments utilizing adipose derived stem cells. The Company will use the credit facility to support working capital and commercialization efforts around its recently launched Celution® System, StemSource® Cell Bank, and product pipeline development.

Cytori Therapeutics received $7.5 million under the new credit facility on October 14, 2008, and has the ability to draw down the remaining $7.5 million by December 12, 2008.

“This financing solution comes at an important time as we recently launched two product lines, which will support the Company’s goal to achieve profitability,” said Mark Saad, Chief Financial Officer of Cytori Therapeutics.

“GE is very pleased to provide capital in support of Cytori’s growth initiatives,” said Anthony Storino, senior managing director, GE Healthcare Financial Services' life science finance group. “Their innovative technologies are shaping the future of the reconstructive surgery markets.”

For almost two decades, the life science finance team of GE Healthcare Financial Services has worked with more than 500 companies throughout the United States, Canada and Europe. With a dedicated focus on assisting life science companies large and small, from the first venture round to post-IPO, the team has provided over $2.5 billion in financing to the market.

Cytori’s (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution® 900 System is being commercialized globally for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.

GE Healthcare Financial Services is the premier provider of capital, financial solutions, and related services for the global healthcare market. With approximately $22 billion in assets, GE Healthcare Financial Services offers a full range of financing capabilities from equipment leasing and real estate financing to working capital lending, vendor programs, and acquisition financing. With a dedicated focus and a deep knowledge of the healthcare industry, GE Healthcare Financial Services collaborates with customers to create tailored financial solutions that help them improve their productivity and profitability. GE Healthcare Financial services in Asia is a division of GE Commercial Finance. For more information, visit www.gehealthcarefinance.com

Media Contact

Jeanee Snipes
GE Healthcare Financial Services
301-634-3210
jeanee.snipes@ge.com